Except for the inevitable acquired resistance, EGFR TKIs are more relevant to EGFR-activating mutations than to WT-EGFR, suggesting that this strategy will achieve relatively little benefit in the majority of lung cancer patients who harboring with WT-EGFR. Here, EGFR is linked to lung cancer.